Cargando…
Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency
Growth hormone insensitivity syndrome (GHI) or insulin-like growth factor-1 (IGF-1) deficiency (IGFD) is characterized by deficit of IGF-1 production due to alteration of response of growth hormone (GH) receptor to GH. This syndrome is due to mutation of GH receptor or IGF-1 gene and patients affect...
Autores principales: | Fintini, Danilo, Brufani, Claudia, Cappa, Marco |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2724186/ https://www.ncbi.nlm.nih.gov/pubmed/19707272 |
Ejemplares similares
-
Mecasermin for primary insulin-like growth factor-1 deficiency
Publicado: (2022) -
Metabolic Syndrome in Italian Obese Children and Adolescents: Stronger Association with Central Fat Depot than with Insulin Sensitivity and Birth Weight
por: Brufani, Claudia, et al.
Publicado: (2011) -
Alterations in Stem Cell Populations in IGF-1 Deficient Pediatric Patients Subjected to Mecasermin (Increlex) Treatment
por: Kamil, Grubczak, et al.
Publicado: (2022) -
Illness Severity, Social and Cognitive Ability, and EEG Analysis of Ten Patients with Rett Syndrome Treated with Mecasermin (Recombinant Human IGF-1)
por: Pini, Giorgio, et al.
Publicado: (2016) -
Recombinant production of mecasermin in E. coli expression system
por: Jafari, S., et al.
Publicado: (2014)